Clinical Trial Update: Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma [Phase 2]

View source ↗

Summary

This update summarizes results from a Phase 2 trial evaluating the combination of bevacizumab (Avastin) and everolimus (RAD001) for advanced clear cell renal ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Everolimus (RAD001, Afinitor) (Everolimus)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-03-06